described the loss of NPM1 mutation at relapse in 9% of NPM1 mutated AML, a finding that alters the prognosis through the selection of clones that harbor FLT3 or DNMT3A mutations exclusively (61). This evidence concerns the gene DNMT3A and acute myeloid leukemia.